The Flu Vaccine study is a Phase II study assessing safety, reactogenicity, and immunogenicity of a Sanofi Pasteur A/H7N9 inactivated Influenza vaccine administered intramuscularly with or without AS03 adjuvant.
This study is open to healthy, HIV-negative adults aged 19 to 64 years of age who have not already received the 2017-2018 flu vaccine. Females able to become pregnant must be willing to use a medically accepted contraceptive method from 30 days before first vaccination until 60 days after the last study vaccination. Participation in this study will last approximately 13 months with up to 8 scheduled clinic visits and 2-7 phone calls depending on which group you are randomized into.
Other inclusion criteria applies. Compensation is provided after enrollment for those who qualify. This study will enroll rapidly over a 12 week period.
For more information or to see if you qualify for this study, please contact us